ReIMAGINE PCa Screening
What is the purpose of this study?
In this study, the standard MRI scan for assessing the prostate, known as multi-parametric MRI, was tested in the community for the first time to see how well it detects prostate abnormalities in 300 men aged 60 to 75 who have no history of prostate cancer.
Why is this research being done?
MRI could be an exciting and effective screening tool, as it’s relatively cheap, widely available, and non-invasive. We want to test if MRI can be used for screening men, and we hope that it will detect serious cancers earlier that are currently being missed. If we can detect cancers earlier and more reliably with a non-invasive test, this could help to improve the survival rates of prostate cancer, and also significantly reduce the number of unnecessary biopsies.
What are the benefits of taking part in the study?
The results of this study will enable us to plan and carry out larger studies to see if MRI really could be a new screening tool for prostate cancer, spotting the cancer early and reducing the need for biopsy.
Who is being included in the study?
Men between the ages of 50 and 75 with no history of prostate cancer were randomly selected from participating GP practices and sent a letter of invitation to a scan. In total, 309 men were recruited for this study.
What is the status of the study?
The ReIMAGINE PCa Screening study has been completed.
Who is carrying out the study?
The study is being conducted by University College London, who is the sponsor of the research. The study is funded by the Medical Research Council and Cancer Research UK, grant no: MR/R014043/1 as part of the MRC’s Stratified Medicine Initiative.
If I have any questions, who can I contact?
For more information about the study see the consortium website https://www.reimagine-pca.org/
View also the ReIMAGINE PCa Screening study record on ClinicalTrials.gov:https://clinicaltrials.gov/ct2/show/NCT04063566
You can also contact us by email at reimagine@ucl.ac.uk